Drug Firm Glenmark Pharmaceuticals On Monday Said It Has Received Approval From The Ministry Of Healthcare, Russia, To Market Montlezir Film-Coated Tablets Used For Treatment Of Allergic Rhinitis. Montlezir Is Expected To Be Available In The Russian Market In Third Quarter Of Financial Year 2019-20, Glenmark Said In A Bse Filing."Russia Is One Of The Key Markets For Us And We Are Consistently Looking To Expand Our Product Portfolio," Glenmark Pharmaceuticals Senior Vice President And Head - Asia, Russia And Cis Region Csaba Kantor Said.Glenmark Has Built Strong Capabilities In The Respiratory Space And Is Among The Leading Players In This Therapy Area Across Several Markets Globally, He Added.According To Iqvia, In The Respiratory Space, Glenmark Continues To Secure A Strong Position And Ranked Fourth Amongst The Companies Present In The Expectorants Market In Russia As Of Mat July 2019, The Company Said.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!